Abbvie submits NDA for HCV regimen

|By:, SA News Editor

The regulatory filing for Abbvie's (ABBV) three-drug regimen for Hepatitis C infection triggers a $20M milestone payment to collaboration partner Enanta Pharmaceuticals (ENTA).

The company developed the protease inhibitor ABT-450 which, in combination with ritonavir, is one leg of the antiviral regimen.

Enanta received $57M from Abbvie when the collaboration was signed and $55M in subsequent milestone payments exclusive of the latest $20M. The firm is eligible to receive up to an additional $175M for regulatory and commercial milestones as well as double digit royalties on global sales.